Deerfield Management Company, L.P.'s Form 4 filing
Larimar Therapeutics, Inc. (LRMR) · filed Feb 16, 2024
- Accession no.
- 0001193805-24-000245
- Filed
- Feb 16, 2024, 2:37 PM ET
- Trade date
- Feb 16, 2024
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $37.5M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deerfield Management Company, L.P.CIK 0001009258 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Mgmt L.P.CIK 0001010823 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Partners, L.P.CIK 0001301041 | Director, 10% Owner, Other: * Director by Deputization |
| Flynn James ECIK 0001352546 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Private Design Fund III, L.P.CIK 0001603333 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Mgmt III, L.P.CIK 0001610540 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Healthcare Innovations Fund, L.P.CIK 0001646981 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Mgmt HIF, L.P.CIK 0001665736 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Private Design Fund IV, L.P.CIK 0001680307 | Director, 10% Owner, Other: * Director by Deputization |
| Deerfield Mgmt IV, L.P.CIK 0001713467 | Director, 10% Owner, Other: * Director by Deputization |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 16, 2024 | Common Stock | PPurchaseAcquired | +1,430,206 | $8.74 | +$12,500,000.44 | 6,151,389 | Indirect | |
| Feb 16, 2024 | Common Stock | PPurchaseAcquired | +1,430,206 | $8.74 | +$12,500,000.44 | 6,151,406 | Indirect | |
| Feb 16, 2024 | Common Stock | PPurchaseAcquired | +1,430,205 | $8.74 | +$12,499,991.7 | 4,207,982 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
Jonathan S. Leff, a partner in Deerfield Management, serves as a director of the Issuer. Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 4 with regard to DA32 Life Science Tech Acquisition Corp. filed with the Securities and Exchange Commission on August 3, 2021 by Deerfield Partners, L.P., Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and James E. Flynn.